Recent PDX treatment shows good response for GLUT inhibitors for lung cancer PDX models (IDs: TC333, TC453, and TC494) carrying KEAP1 or NFE2L2 mutations37. This evidence concerns the gene SLC2A1 and lung carcinoma.